2
Clinical Trials associated with CD19 UCAR-T cell therapy(Shanghai Longyao Biotech Co., Ltd.)To evaluate the safety and tolerability of CD19 UCAR-T cell injection in subjects with relapsed/refractory CD19-positive B-cell malignancies
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
This is a single arm, open-label, single center, exploratory clinical study to evaluate the safety and efficacy of CD19 UCAR-T Cells in Patients With CD19+ B-cell acute lymphoblastic leukemia (B-ALL).
100 Clinical Results associated with CD19 UCAR-T cell therapy(Shanghai Longyao Biotech Co., Ltd.)
100 Translational Medicine associated with CD19 UCAR-T cell therapy(Shanghai Longyao Biotech Co., Ltd.)
100 Patents (Medical) associated with CD19 UCAR-T cell therapy(Shanghai Longyao Biotech Co., Ltd.)
100 Deals associated with CD19 UCAR-T cell therapy(Shanghai Longyao Biotech Co., Ltd.)